{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:13Z","timestamp":1777934533348,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1177\/10781552211016078","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T06:18:51Z","timestamp":1621491531000},"page":"1248-1250","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["The regulatory saga of fedratinib"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4477-0448","authenticated-orcid":false,"given":"Shannon","family":"Khal","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Providence Centralia Hospital, Centralia, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, CA, USA\u202f"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8635-9337","authenticated-orcid":false,"given":"Alison","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Oregon Health and Science University, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"bibr1-10781552211016078","unstructured":"Robie-Suh K. Center for drug evaluation and research multi-discipline review, Application Number: 212327Orig1s000, www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212327Orig1s000MultidisciplineR.pdf (2019, accessed 6 February 2020)."},{"key":"bibr2-10781552211016078","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"bibr3-10781552211016078","unstructured":"Taylor NP, Idrus AA, Adams B. Second phase III study of novartis JAK inhibitor INC424 meets primary endpoint in patients with myelofibrosis. FierceBiotech, www.fiercebiotech.com\/biotech\/second-phase-iii-study-of-novartis-jak-inhibitor-inc424-meets-primary-endpoint-patients. (2011, accessed 26 April 2021)."},{"key":"bibr4-10781552211016078","unstructured":"Incyte announces positive top-line results from COMFORT-I Pivotal Phase III Trial of INCB18424 in Myelofibrosis, a Debilitating, Life-Threatening Blood Cancer.\n                      Incyte Corporation\n                      , https:\/\/investor.incyte.com\/press-releases\/press-releases\/2010\/Incyte-Announces-Positive-Top-Line-Results-from-COMFORT-I-Pivotal-Phase-III-Trial-of-INCB18424-in-Myelofibrosis-a-Debilitating-Life-Threatening-Blood-Cancer\/default.aspx (2010, accessed 11 May 2021)."},{"key":"bibr5-10781552211016078","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"bibr6-10781552211016078","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0167"},{"key":"bibr7-10781552211016078","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"bibr8-10781552211016078","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7057"},{"key":"bibr9-10781552211016078","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood-2017-05-785790","volume":"130","author":"Harrison CN","year":"2017","journal-title":"Blood"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211016078","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211016078","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211016078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:24:55Z","timestamp":1777688695000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211016078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1177\/10781552211016078"],"URL":"https:\/\/doi.org\/10.1177\/10781552211016078","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]}}}